– UK, Belfast – Diaceutics PLC (LON: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announced the appointment of Cheryl MacDiarmid to its Board as a Non-Executive Director subject to due diligence checks. Current Non-Executive Director Graham Paterson will assume the role of Senior Independent Director effective 1 October 2024.
Current CDO Jordan Clark will also join the Board as an Executive Director effective 1 October 2024, while Mike Wort is stepping down as a Non-Executive Director effective 1 October 2024.
Peter Keeling, Non-Executive Chair of Diaceutics said: “I am delighted to warmly welcome Cheryl and Jordan to the Board of Diaceutics. They both bring a significant depth of talent and vast experience as leaders in their field to Diaceutics and I know their insights will play a significant part in helping drive our continued performance and growth in the years ahead.”
About Cheryl MacDiarmid
Cheryl MacDiarmid has over 30 years of experience in the global pharmaceutical sector, notably with GSK, and ViiV Healthcare, and currently as a Non-Executive Director of AIM-listed Allergy Therapeutics. Cheryl is an internationally recognized opinion leader in the development & commercialization of medicines. Trained as a pharmacist, she has held numerous senior leadership positions in the UK, EU, US, and Canada, with responsibilities including global commercial strategy, P&L, sales, marketing, operations, and Board membership. Cheryl is passionate about bringing new therapies to the right patients who can benefit.
About Jordan Clark
Jordan Clark is the CDO at Diaceutics. Jordan spearheads Diaceutics’ comprehensive data strategy, spanning acquisition engineering and data science, to deliver cutting-edge analytics to our clients and laboratories. With over a decade of experience at Diaceutics, he has cultivated a profound understanding of the critical role real-world data plays in optimizing precision medicine. Jordan’s academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a hematology scientist, underscore his expertise. Additionally, Jordan is renowned for proficiency testing, bioinformatics, and biomarker testing, honed through his involvement with UK NEQAS.
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialization solution for precision medicines through data analytics, and scientific and advisory services enabled by our platform DXRX – The Diagnostics Network.
For more: https://www.diaceutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.